Calculate the score correctly, apply age-appropriate thresholds, and understand when another assessment is needed.
A FIB-4 score estimates the probability of advanced liver fibrosis using age, AST, ALT, and platelet count. It is a risk-stratification calculation, not a direct measurement of liver function, fat, or scar tissue. A low score does not prove that the liver is healthy, and a high score does not diagnose cirrhosis.
Ulta Lab Tests provides access to laboratory measurements used in the calculation. The results should be interpreted by a qualified healthcare professional, especially when values are abnormal, age affects the threshold, or there is known liver disease. This guide explains the arithmetic and its limits; the MASLD fibrosis assessment pathway covers disease-specific follow-up in greater depth.
Fibrosis is scar tissue that develops after repeated liver injury. Advanced fibrosis generally refers to F3–F4, with F4 representing cirrhosis. Clinically significant fibrosis can begin at F2. The numerical FIB-4 result is not a stage: a score of 2 does not mean F2, and a score of 4 does not mean F4.
The score was developed as a noninvasive assessment using readily available information. It is now used in several liver-disease settings, including metabolic dysfunction-associated steatotic liver disease, or MASLD. Its performance depends on the population and clinical purpose; thresholds used for MASLD should not automatically be transferred to every other liver condition.
In an appropriate primary-care setting, one important use is identifying people with a lower probability of advanced fibrosis. It can also identify people who need a more specific assessment. Its limitations mean it cannot exclude every case of MASH or clinically important fibrosis. The AASLD guidance emphasizes interpreting noninvasive thresholds in context.
| Situation | Why it may matter | Useful information |
|---|---|---|
| Type 2 diabetes or multiple cardiometabolic risks | May justify fibrosis-risk assessment even with normal enzymes | Current AST, ALT, platelet count, age, and clinical history |
| Fatty liver noted on imaging | Steatosis does not identify fibrosis stage | Existing imaging report and appropriate laboratory inputs |
| Persistently abnormal liver enzymes | Fibrosis risk and the cause of injury need separate consideration | Exposure history, previous results, and clinician-selected testing |
| Acute illness or a temporary platelet disturbance | Can distort the calculation | Clinical assessment before using the score as a chronic baseline |
| Age younger than 35 | Low accuracy limits reassurance from a low score | Alternative assessment when clinical concern is substantial |
FIB-4 is not a universal wellness screen. People with known advanced liver disease, acute symptoms, or imaging suggesting cirrhosis may need direct assessment regardless of a calculated score. For an introduction to the underlying condition, read what MASLD blood tests can reveal.
| Input | What it represents | Units or source | Important limitation |
|---|---|---|---|
| Age | Age when the laboratory values were collected | Years | Age can increase the score even when laboratory results stay unchanged |
| AST | An enzyme found in liver, muscle, and other tissues | U/L | Muscle injury or exercise can contribute to elevation |
| ALT | An enzyme more concentrated in liver cells | U/L | Normal values do not exclude liver disease; acute changes can distort the score |
| Platelet count | Circulating blood platelets | ×109/L, often reported in a CBC | Low platelets can have causes unrelated to fibrosis |
Check that all results belong to the same patient and refer to an appropriate collection period. Use age at collection for historical calculations. Combining an old enzyme result with a new blood count can create a number that does not represent a real clinical state.
Multiply age by AST, then divide by platelet count multiplied by the square root of ALT.
FIB-4 = (age in years × AST in U/L) ÷ [platelets in ×109/L × √(ALT in U/L)]
This fictional example uses age 50 years, AST 40 U/L, ALT 35 U/L, and platelets 200 ×109/L. The calculation is (50 × 40) ÷ (200 × √35).
The square root of 35 is approximately 5.916. The numerator is 2,000, and the denominator is approximately 1,183.216. The FIB-4 result is approximately 1.6903, commonly displayed as 1.69.
For an adult of this age in a common MASLD pathway, 1.69 is indeterminate and supports discussion of secondary assessment. It does not establish fibrosis or cirrhosis. Avoid rounding the inputs before calculation; small changes near a decision threshold should be interpreted clinically.
A platelet count of 200 ×109/L is numerically equivalent to 200 ×103/µL or 200 K/µL. Enter 200 in this formula. A count written as 200,000/µL needs conversion to the required numeric convention. Entering 200,000 without conversion produces a misleadingly tiny score.
Do not calculate from missing values, a reported zero platelet count, or a nonpositive ALT. Those situations need clarification of the report or clinical assessment. Check the square-root operation and parentheses carefully; dividing by ALT directly is not the FIB-4 formula.
| Age | Lower probability | Indeterminate | Higher concern |
|---|---|---|---|
| 35–64 years | Below 1.3 | 1.3–2.67 | Above 2.67 |
| 65 years or older | Below 2.0 | 2.0–2.67 | Above 2.67 |
| Younger than 35 | Standard thresholds are less reliable. Consider alternative assessment when risk or liver abnormalities warrant it. | ||
The AGA summary places adults aged 65 or older in the higher lower-risk threshold group; AASLD's earlier wording refers to those older than 65. Follow the clinician's chosen pathway at this boundary. The older-adult adjustment reduces false-positive concern related to age; it does not remove the need to assess symptoms, other abnormalities, or persistent clinical concern.
For illustration, keeping AST 40 U/L, ALT 35 U/L, and platelets 200 ×109/L unchanged but using age 70 produces a score of approximately 2.37. This arithmetic comparison demonstrates the age effect. It does not prove that fibrosis progressed between age 50 and age 70.
The next step depends on the whole clinical picture, not just which box contains the score. A lower-risk result may support ongoing metabolic management and periodic reassessment. Persistent enzyme elevation, concerning imaging, or strong clinical suspicion can still justify further evaluation.
An indeterminate score usually prompts a second assessment such as vibration-controlled transient elastography, commonly called FibroScan, or an Enhanced Liver Fibrosis (ELF) Score. A result above 2.67 generally supports specialist referral or further risk stratification. These findings should not be converted into a self-diagnosis of cirrhosis.
ELF is a blood-based composite score; elastography is an imaging-based stiffness assessment arranged through clinical services. Biopsy may be considered when uncertainty remains and a tissue answer would change care. The detailed MASLD fibrosis pathway explains how secondary thresholds differ by purpose and why conflicting tests need clinical review.
| Test or panel | Why it may be used | Important limit |
|---|---|---|
| AST | Supplies the numerator's enzyme value | Can rise from muscle or other non-liver sources |
| ALT | Supplies the enzyme value used under the square root | Is not a direct fibrosis measurement |
| Platelet count | Supplies the platelet denominator | Verify units and consider unrelated platelet disorders |
| CBC with Differential and Platelets | Provides platelets and broader blood-cell information | A separate platelet count may duplicate information already available |
| Comprehensive Metabolic Panel (CMP) | Includes AST and ALT with additional metabolic chemistry | Does not replace the platelet measurement |
| Hepatic Function Panel | Includes AST and ALT in focused liver chemistry testing | Overlaps with CMP and does not supply the platelet input |
| FIB-4 Index Liver Health Evaluation (Self Calculation) | An Ulta-listed option related to obtaining calculation inputs | Read the current product components and reporting instructions; age is not a blood-test measurement |
| Enhanced Liver Fibrosis (ELF) Score | May add secondary fibrosis-risk information | Not automatically necessary for every low-risk result |
If suitable results already exist, ask whether they can be used. When new testing is needed, choose a coherent set rather than ordering every panel in the table. Review the current components, preparation instructions, and how the result or calculation will be supplied.
Every input affects the arithmetic. Aging increases the numerator. A muscle-related AST rise also increases it. A platelet fall decreases the denominator, raising the score regardless of why the count fell. If only ALT falls while the other inputs stay unchanged, the denominator becomes smaller and the score can rise.
That mathematical behavior is why a rising score cannot automatically be labeled worsening fibrosis. Equally, a falling score does not independently prove regression. Review the direction of each input, collection circumstances, symptoms, and secondary assessments. Changes in noninvasive markers can be clinically useful, but are not identical to direct evidence of scar-tissue change.
Recent infection, acute illness, strenuous exercise, muscle injury, alcohol exposure, medicines, and sample problems can affect interpretation. A clinician may repeat selected measurements after a temporary influence resolves, or proceed to another assessment when concern remains. The metabolic dashboard article explains how glucose, lipid, kidney, and liver trends can differ.
There is no universal six- or twelve-month interval for every person. AASLD commonly suggests one- to two-year reassessment for people with prediabetes, type 2 diabetes, or multiple metabolic risks; selected people without prediabetes or diabetes and with fewer risks may be reassessed every two to three years. The AGA pathway uses one- to two-year reassessment for low-risk patients.
The clinician selects the interval and may assess sooner after an unexpected change or new concern. An indeterminate or high result generally needs secondary assessment rather than waiting for the next routine calculation. Known advanced disease requires an individualized monitoring plan that cannot be reduced to FIB-4 alone.
The calculation itself does not require fasting. Accompanying laboratory tests may have preparation requirements, so follow the specific order instructions. Bring the requested identification and collection paperwork. Report recent illness, strenuous exercise, alcohol, and all medicines or supplements. Do not stop prescribed medication without prescriber guidance.
Before the follow-up conversation, note the collection date, units, reference intervals, current symptoms, and previous values. Reference intervals describe a laboratory's comparison population; FIB-4 cutoffs are clinical decision thresholds used in defined settings. Neither should be replaced with an unsupported “optimal liver score.”
New confusion, vomiting blood, or black tarry stools with fainting or marked weakness can require emergency care. New jaundice, rapidly increasing abdominal swelling, or severe abdominal pain with systemic illness needs urgent assessment. Do not use a low FIB-4 score to dismiss these symptoms or wait for online testing.
Ulta Lab Tests provides access to many relevant laboratory measurements online where available. Patients can review listed prices, use established laboratory services including Quest Diagnostics where applicable, and receive results securely online. Insurance is not required; eligible HSA/FSA payment may be available. Ordering laboratory inputs does not replace clinician interpretation or arrange imaging automatically.
It is better to describe lower-risk categories than a universally normal value. Many MASLD pathways use below 1.3 for adults aged 35–64 and below 2.0 for older adults. A lower score reduces advanced-fibrosis probability in the appropriate setting but does not prove a healthy liver or exclude every liver disorder.
No. It estimates risk and helps identify people who may need another assessment. A high result can reflect advanced liver disease, but age, acute illness, muscle-related AST elevation, and non-liver platelet disorders can contribute. Clinicians integrate the result with other findings before diagnosing cirrhosis or planning disease-specific care.
Use the numeric value expressed in ×109/L. For example, 200 ×109/L, 200 K/µL, and 200 ×103/µL all use 200 in the formula. A report expressed as 200,000/µL requires conversion. Verify the notation rather than copying an unfamiliar number directly.
The square-root term is part of the validated FIB-4 formula. Dividing by ALT itself, omitting the square root, or placing parentheses incorrectly produces a different calculation. Use the full expression and correct units. The formula's mathematics should not be interpreted as a direct biological measurement of scar tissue.
Yes. If ALT alone falls while age, AST, and platelets remain unchanged, the denominator becomes smaller and the calculated score rises. Real results often involve several changing inputs. A clinician reviews those changes and the clinical context; this arithmetic effect does not automatically indicate worsening liver fibrosis.
Results from the same collection are preferable. Combining values from different dates may mix distinct clinical states, especially after illness, exercise, medication changes, or a platelet disturbance. Ask whether existing measurements are sufficiently comparable before calculating. Use age at the collection date when assessing historical results.
Not necessarily. An indeterminate or high result generally needs further assessment, but the appropriate choice may be elastography, ELF, direct specialist review, or another strategy. Availability, symptoms, previous imaging, and the suspected liver condition matter. The next step should answer the remaining clinical question rather than follow an automatic purchasing rule.
The score itself has no fasting requirement. However, it may be calculated from laboratory testing ordered with other measurements that do require preparation. Follow the actual test instructions and report recent meals, illness, exercise, alcohol, and medicines where relevant. Do not change prescribed treatment simply to prepare without clinical guidance.
Correct arithmetic is only the first step. Explore the linked testing options if inputs are needed, confirm the relevant clinical pathway, and make a follow-up plan with a qualified healthcare professional. For broader interpretation of liver chemistry, see the Liver Function Tests guide.
Originally published: May 7, 2026 | Updated: September 18, 2026
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
